Patent-Pending Formula

A New Mechanistic Approach to
Migraine Management

A patent applied synergistic formulation targeting novel molecular pathways in migraine pathophysiology.

Innovative Molecular Targeting

CephaMig™ modulates previously unaddressed molecular pathways including mast cells, microglia, PPAR-α, and TRPV1 receptors—bridging the gap left by conventional migraine therapies.

Clinically Proven Efficacy

Demonstrated reduction in migraine frequency, intensity, and duration with decreased dependence on rescue medication.

Safe and Well-Tolerated

Composed of clinically validated ingredients with proven safety across multiple studies and regulatory frameworks.

Science Meets Precision

CephaMig™ represents the evolution of migraine management—where neuroscience, molecular pharmacology, and clinical evidence converge.

Our research-driven approach identifies and modulates critical pathways in neuroinflammation, improving patient outcomes without adverse effects.

Key Focus Areas

Neuroinflammation and mast cell modulation
PPAR-α and TRPV1 receptor targeting
Enhanced neural stability and reduced pain signaling
Complementary to conventional antimigraine therapies

“CephaMig™ Defining a New Era in Migraine Science”

Developed through years of clinical research, CephaMig™ stands as a patent applied international innovation for migraine prophylaxis.

Discover the Science Behind CephaMig™

CephaMig™ is the result of advanced research integrating palmitoylethanolamide (PEA), Ginkgolide-B, and Magnesium—a synergistic composition designed to optimize neuronal balance and reduce migraine burden.

Palmitoylethanolamide (PEA)

Targets neuroinflammation and stabilizes mast cell activity to prevent migraine initiation.

Ginkgolide-B

Inhibits platelet-activating factor (PAF), reducing vascular instability and aura symptoms.

Magnesium

Supports neuronal energy balance and mitigates excitotoxicity associated with migraine attacks.

Recognized by Global Experts

“CephaMig™ represents a significant advancement in migraine prevention through multi-target molecular modulation.”

— Clinical Investigator

From Research to Real-World Impact

By modulating neuroinflammatory and neurosensory pathways, CephaMig™ achieves multifactorial migraine prevention. It offers neuroprotection, reduced attack frequency, and enhanced quality of life through a validated, multimodal novel molecular target based mechanism.

We Are Pioneers in
Migraine Science

Advancing the understanding, prevention, and management of migraine through a novel, patent applied molecular approach.

Innovative Neurological Research

Exploring new pathways in migraine pathophysiology through molecular targeting.

Clinically Validated Mechanisms

Supported by preclinical and clinical studies demonstrating measurable improvement.

Patent applied Synergistic Composition

Combines PEA, Ginkgolide-B, and Magnesium for enhanced neuroprotection.

Global Scientific Recognition

Developed and reviewed by experts for international patent protection.

Comprehensive Scientific Innovation

CephaMig™ represents a major milestone in neurological research and migraine management. Designed through years of molecular study, it targets mechanisms unaddressed by conventional antimigraine drugs.

By modulating mast cell activation, neuroinflammatory signaling, and receptor desensitization, CephaMig™ offers a truly comprehensive approach to migraine prophylaxis.

Its development was guided by a clear scientific mission—to provide a safe, synergistic, and patent-backed formulation that delivers consistent outcomes validated through both laboratory and clinical studies.

— Scientific Development Team, CephaMig™ Research Division

Addressing Migraine at Its Molecular Roots

Our philosophy is preventive and mechanistic. We aim to address the underlying molecular imbalances that contribute to migraine onset—long before symptoms arise.

Vision

To redefine migraine care through molecular innovation and scientific collaboration.

Mission

To develop formulations that combine validated bioactives targeting inflammation and neuroprotection.

Technology

Leveraging advanced molecular modeling, bioassays, and clinical research.

Our Research & Development Team

Combining expertise in neurology, pharmacology, and biomedical innovation.

Clinical Pharmacologists
Formulation Experts
Regulatory Specialists

“We created CephaMig™ because migraine sufferers deserve more than temporary relief. They deserve a targeted, research-backed solution.”

— The Founding Team

“CephaMig™ demonstrates how molecular precision and scientific integrity can converge to transform migraine prevention.”

— Lead Investigator, CephaMig™ Project

What Experts Are Saying

Endorsements from medical professionals and clinical researchers worldwide.

“A breakthrough formulation addressing neuroinflammation and pain modulation with impressive safety.”

— Clinical Pharmacologist, India

“The multi-target approach of CephaMig™ makes it a true innovation in migraine management.”

— Neurology Research Journal, 2024

“The combination of PEA, Ginkgolide-B, and Magnesium is scientifically sound and synergistic.”

— European Neurochemistry Review

Our Scientific Process

From molecular insight to patent applied innovation — CephaMig™ follows a rigorous scientific and clinical validation pathway.

Molecular Target Identification

Discovering novel molecular pathways such as mast cells, microglia, PPAR-α, and TRPV1 receptors implicated in migraine genesis.

Formulation Design & Development

Integrating synergistic bioactives — Palmitoylethanolamide, Ginkgolide-B, and Magnesium — into a patentable and effective composition.

Clinical Evaluation & Validation

Conducting controlled studies to assess efficacy, safety, and synergistic potential in reducing migraine frequency and duration.

Global Patent & Scientific Recognition

Protecting intellectual property and ensuring international recognition under scientific and regulatory frameworks.

Evidence-Based Development

Every stage of CephaMig™ development is guided by molecular biology, clinical pharmacology, and neuroscience research.

Our laboratories employ advanced analytical models and standardized protocols to validate every component and its interaction.

Molecular Screening: Identification of neuroinflammatory and receptor-level targets.
In-Vitro Testing: Evaluation of bioactive stability and interaction at the cellular level.
Preclinical Studies: Confirmation of efficacy in experimental migraine models.
Clinical Validation: Human studies demonstrating safety, tolerability, and measurable outcomes.

The Research-to-Formula Pathway

Our process ensures that CephaMig™ is not just innovative but scientifically reproducible, globally credible, and regulatory-compliant.

Concept & Hypothesis

Identifying unaddressed pain mechanisms and proposing a synergistic bioactive hypothesis.

Mechanism Validation

Testing the interaction of PEA, Ginkgolide-B, and Magnesium through in-vitro and in-vivo pathways.

Clinical Demonstration

Evaluating real-world impact through statistically significant improvement in migraine parameters.

Scientific Collaboration at Every Step

From hypothesis to formulation — a multidisciplinary approach drives CephaMig™’s success.

Approach

Our philosophy blends molecular innovation with patient-centric goals — focusing on prevention through mechanism-based therapy.

Experts

Our research consortium includes pharmacologists, neuroscientists, and clinical investigators with decades of experience in migraine biology.

Technology

We employ molecular docking, biochemical assays, and receptor-binding analyses to validate each ingredient’s contribution to the overall effect.

Comprehensive Scientific Validation

CephaMig™’s formulation is backed by a complete validation cycle — from molecular rationale to real-world evidence — ensuring trust, reproducibility, and global scientific acceptance.

Molecular Characterization

Confirming purity, stability, and compatibility of all bioactive components.

Safety & Pharmacovigilance

Continuous safety monitoring and pharmacovigilance data to ensure the highest scientific integrity.

Clinical Translation

Bridging laboratory innovation to clinical reality through data-driven translational research.

How Can the Future of Migraine Management Be Transformed?

By addressing molecular mechanisms beyond conventional therapies.

CephaMig™ pioneers this transformation through targeted, patent-applied innovation designed for neurological well-being and scientific progress.

Neuroprotective Mechanisms Inflammation Control Pathways Synergistic Molecular Action Long-Term Migraine Prophylaxis

Research and Scientific Validation

From molecular discovery to clinical outcomes — the science behind CephaMig™ demonstrates how innovation meets evidence in migraine management.

Understanding Migraine at the Molecular Level

CephaMig™ is a patent applied formulation developed through a decade of research into the neuroinflammatory pathways that trigger migraine onset and persistence.

By focusing on mast cell modulation, microglial regulation, PPAR-α activation, and TRPV1 desensitization, CephaMig™ addresses multiple mechanisms left uncorrected by traditional therapies.

Approach

Targeting key cellular mediators of inflammation.

Experts

Developed by neuroscientists & pharmacologists.

Technology

Backed by molecular modeling & biomarker evaluation.

Facilities

Conducted under internationally accredited labs.

The CephaMig™ Mechanism of Action

CephaMig™ works through synergistic molecular modulation, targeting the root causes of migraine rather than only symptoms.

Mast Cell Stabilization Reduces neuroinflammation and hypersensitivity.
Microglial Modulation Controls cytokine-mediated pain signaling.
PPAR-α Activation Promotes neuronal protection and facilitates anti-inflammatory effect.
TRPV1 Receptor Desensitization Minimizes vascular and sensory overactivation.